Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCTB39-1 in advanced malignant solid tumours
NCT07050641Phase 2Recruiting
- Sponsor
- Sinocelltech Group Limited
- Start
- Jun 2025
- Primary completion
- Jun 2028
- Modality
- Trispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of SCTB39G in malignant solid tumor, sponsored by Sinocelltech Group Limited. Started Jun 2025; status: recruiting.
02
Drugs
SCTB39G
03
Conditions
malignant solid tumor
Beyond the preview
Go deeper on NCT07050641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07050641.